Back to search

Article

A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer

2023-09-12

Abstract excerpt

<h4>Background: </h4> Hyperglycemia is an on-target effect of PI3Kα inhibitors. Early identification and intervention of treatment-induced hyperglycemia is important for improving management of patients receiving a PI3Kα inhibitor like alpelisib. Here we characterize early grade 3/4 alpelisib-related hyperglycemia, along with associated incidence, management, and outcomes using a machine learning model. <h4>Metho...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
50085aaf-d4f6-596f-a3f0-828150c0bc22
DOI
10.21203/rs.3.rs-3275727/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerDOI 10.21203/rs.3.rs-3275727/v1
Distinct glycaemic safety reporting patterns for alpelisib and capivasertib: a disproportionality analysis of the FAERS databaseSemantic proximity
Observations with alpelisib in older patients (≥ 65 year of age) with breast cancer in a non-clinical trial setting.Semantic proximity
Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programSemantic proximity
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity
WITHDRAWN: A Machine Learning Model for Real-Time Hypoglycemia Risk Prediction in Hospitalized Diabetic Patients: Development and ValidationSemantic proximity
Predicting Hypoglycemia in Elderly Inpatients with Type 2 Diabetes: The ADOCHBIU ModelSemantic proximity
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.Semantic proximity
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.Semantic proximity
Genetic risk of prediabetes and diabetes development in chronic myeloid leukemia patients treated with nilotinib.Semantic proximity
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.Semantic proximity
Select a neighboring publication to make it the new centre.